Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Drew

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Blood Advances|May 15, 2023
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5Derek B Oien, Samanta Sharma, Maureen M Hattersley, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 30, 2020
Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991Ardeshir Goliaei, Haley A Woods, Adriana E Tron, et al.
British Journal of Cancer|May 15, 2018
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic statusRui Ma, Ling Xu, Xiujuan Qu, et al.
Cancer Research|June 19, 2008
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanomaClara Montagut, Sreenath V Sharma, Toshi Shioda, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2011
3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitorDavid A Scott, Les A Dakin, David J Del Valle, et al.
Molecular Cancer Therapeutics|June 28, 2019
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell LymphomaTaylor Hashiguchi, Nur Bruss, Scott Best, et al.
Blood|December 1, 2020
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomasScott Boiko, Theresa Proia, Maryann San Martin, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2008
3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profileDavid A Scott, Kirsten J Bell, Cheryl T Campbell, et al.
Oncogene|March 12, 2003
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding siteTamara N Do, Ramon V Rosal, Lisa Drew, et al.
Bioorganic & Medicinal Chemistry|February 6, 2018
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4Sébastien L Degorce, Rana Anjum, Keith S Dillman, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Blood Advances|May 15, 2023
BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5Derek B Oien, Samanta Sharma, Maureen M Hattersley, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 30, 2020
Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991Ardeshir Goliaei, Haley A Woods, Adriana E Tron, et al.
British Journal of Cancer|May 15, 2018
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic statusRui Ma, Ling Xu, Xiujuan Qu, et al.
Cancer Research|June 19, 2008
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanomaClara Montagut, Sreenath V Sharma, Toshi Shioda, et al.
Bioorganic & Medicinal Chemistry Letters|February 8, 2011
3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitorDavid A Scott, Les A Dakin, David J Del Valle, et al.
Molecular Cancer Therapeutics|June 28, 2019
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell LymphomaTaylor Hashiguchi, Nur Bruss, Scott Best, et al.
Blood|December 1, 2020
Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomasScott Boiko, Theresa Proia, Maryann San Martin, et al.
Bioorganic & Medicinal Chemistry Letters|December 31, 2008
3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profileDavid A Scott, Kirsten J Bell, Cheryl T Campbell, et al.
Oncogene|March 12, 2003
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding siteTamara N Do, Ramon V Rosal, Lisa Drew, et al.
Bioorganic & Medicinal Chemistry|February 6, 2018
Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4Sébastien L Degorce, Rana Anjum, Keith S Dillman, et al.
Pageof 5